Protonitazepyne

Protonitazepyne

Protonitazepyne

Chemical compound


Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in Canada in early 2023. It is an analogue of etonitazene where the ethoxy group has been extended to propoxy, and the N,N-diethyl substitution has been cyclised into a pyrrolidine ring. While formal studies into its pharmacology have yet to be carried out, it is believed to be slightly less potent than the ethoxy analogue etonitazepyne but still a potent opioid.[1][2]

Quick Facts Identifiers, PubChem CID ...

See also


References

  1. "Early signal alert: Emergence of online mentions of Protonitazepyne". National Drug Early Warning System. 29 July 2022.
  2. "Analyzed Drug Report" (PDF). Drug Analysis Service and Cannabis Laboratories. Health Canada. April–June 2023.




Share this article:

This article uses material from the Wikipedia article Protonitazepyne, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.